Irinotecan liposome with immunotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer that has spread beyond one lung and hasn't been treated before.
- You need to be between 18 and 70 years old.
- You must be in good enough health to perform daily activities (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a CT scan and hasn't been treated with radiation.
- Your liver, kidneys, and blood counts must be working well enough (specific lab tests required).
- If you could become pregnant, you must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted/immune drugs with standard chemotherapy as a first treatment for extensive small cell lung cancer. It aims to see if this approach is safe and effective for people who have not had prior treatment for this cancer.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.